Tags

Type your tag names separated by a space and hit enter

Development of a LC/MS/MS method for the analysis of cannabinoids in human EDTA-plasma and urine after small doses of Cannabis sativa extracts.

Abstract

A novel high-performance liquid chromatographic separation method with tandem-mass spectrometry detection was developed for the simultaneous determination of Delta(9)-tetrahydrocannabinol (THC) and its major metabolites 11-hydroxy-Delta(9)-tetrahydrocannabinol (11-OH-THC) and 11-nor-Delta(9)-tetrahydrocannabinol-9-carboxylic acid (THC-COOH) as well as the components cannabidiol (CBD) and cannabinol (CBN) in human EDTA-plasma and urine. Run time was 25 min. Lower limit of quantification was 0.2 ng/ml. The coefficients of variation of all inter- and intra-assay determinations were between 1.3 and 15.5%. The method was successfully applied to the determination of cannabinoids in human plasma and human urine after administration of Delta(9)-tetrahydrocannabinol or Cannabis sativa extracts.

Authors+Show Affiliations

Clinical Chemical Laboratory, Toxicology Section, University Hospital, Petersgraben 4, 4031 Basel, Switzerland.No affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

17236827

Citation

Grauwiler, Sandra B., et al. "Development of a LC/MS/MS Method for the Analysis of Cannabinoids in Human EDTA-plasma and Urine After Small Doses of Cannabis Sativa Extracts." Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences, vol. 850, no. 1-2, 2007, pp. 515-22.
Grauwiler SB, Scholer A, Drewe J. Development of a LC/MS/MS method for the analysis of cannabinoids in human EDTA-plasma and urine after small doses of Cannabis sativa extracts. J Chromatogr B Analyt Technol Biomed Life Sci. 2007;850(1-2):515-22.
Grauwiler, S. B., Scholer, A., & Drewe, J. (2007). Development of a LC/MS/MS method for the analysis of cannabinoids in human EDTA-plasma and urine after small doses of Cannabis sativa extracts. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences, 850(1-2), pp. 515-22.
Grauwiler SB, Scholer A, Drewe J. Development of a LC/MS/MS Method for the Analysis of Cannabinoids in Human EDTA-plasma and Urine After Small Doses of Cannabis Sativa Extracts. J Chromatogr B Analyt Technol Biomed Life Sci. 2007 May 1;850(1-2):515-22. PubMed PMID: 17236827.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Development of a LC/MS/MS method for the analysis of cannabinoids in human EDTA-plasma and urine after small doses of Cannabis sativa extracts. AU - Grauwiler,Sandra B, AU - Scholer,André, AU - Drewe,Jürgen, Y1 - 2007/01/11/ PY - 2006/10/13/received PY - 2006/12/15/revised PY - 2006/12/22/accepted PY - 2007/1/24/pubmed PY - 2007/7/25/medline PY - 2007/1/24/entrez SP - 515 EP - 22 JF - Journal of chromatography. B, Analytical technologies in the biomedical and life sciences JO - J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. VL - 850 IS - 1-2 N2 - A novel high-performance liquid chromatographic separation method with tandem-mass spectrometry detection was developed for the simultaneous determination of Delta(9)-tetrahydrocannabinol (THC) and its major metabolites 11-hydroxy-Delta(9)-tetrahydrocannabinol (11-OH-THC) and 11-nor-Delta(9)-tetrahydrocannabinol-9-carboxylic acid (THC-COOH) as well as the components cannabidiol (CBD) and cannabinol (CBN) in human EDTA-plasma and urine. Run time was 25 min. Lower limit of quantification was 0.2 ng/ml. The coefficients of variation of all inter- and intra-assay determinations were between 1.3 and 15.5%. The method was successfully applied to the determination of cannabinoids in human plasma and human urine after administration of Delta(9)-tetrahydrocannabinol or Cannabis sativa extracts. SN - 1570-0232 UR - https://www.unboundmedicine.com/medline/citation/17236827/Development_of_a_LC/MS/MS_method_for_the_analysis_of_cannabinoids_in_human_EDTA_plasma_and_urine_after_small_doses_of_Cannabis_sativa_extracts_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S1570-0232(06)01050-6 DB - PRIME DP - Unbound Medicine ER -